Pharmaceutical Company Seeks High Court Review In Trademark Dispute
WASHINGTON, D.C. — A pharmaceutical company in an Oct. 20 petition for writ of certiorari asks the U.S. Supreme Court to answer whether Sections 14(3) and 43(a) of the Lanham Act...To view the full article, register now.
Already a subscriber? Click here to view full article